1. Home
  2. OPAD vs ALLR Comparison

OPAD vs ALLR Comparison

Compare OPAD & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OPAD

Offerpad Solutions Inc.

HOLD

Current Price

$0.62

Market Cap

29.8M

Sector

Finance

ML Signal

HOLD

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

HOLD

Current Price

$1.61

Market Cap

26.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPAD
ALLR
Founded
2015
2004
Country
United States
United States
Employees
140
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.8M
26.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
OPAD
ALLR
Price
$0.62
$1.61
Analyst Decision
Buy
Strong Buy
Analyst Count
4
1
Target Price
$1.83
$9.75
AVG Volume (30 Days)
588.7K
251.9K
Earning Date
04-30-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$320,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$32.08
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$0.77
52 Week High
$6.35
$2.35

Technical Indicators

Market Signals
Indicator
OPAD
ALLR
Relative Strength Index (RSI) 38.69 50.75
Support Level $0.60 $1.51
Resistance Level $0.90 $1.80
Average True Range (ATR) 0.06 0.16
MACD 0.00 -0.01
Stochastic Oscillator 13.36 41.71

Price Performance

Historical Comparison
OPAD
ALLR

About OPAD Offerpad Solutions Inc.

Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services, including mortgage, listing, renovation, and buyer representation services.

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

Share on Social Networks: